225 related articles for article (PubMed ID: 37451269)
1. Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer.
Gomes I; Gallego-Paez LM; Jiménez M; Santamaria PG; Mansinho A; Sousa R; Abreu C; Suárez EG; Costa L; Casimiro S
Cell Rep Med; 2023 Aug; 4(8):101120. PubMed ID: 37451269
[TBL] [Abstract][Full Text] [Related]
2. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
3. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
De Angelis C; Fu X; Cataldo ML; Nardone A; Pereira R; Veeraraghavan J; Nanda S; Qin L; Sethunath V; Wang T; Hilsenbeck SG; Benelli M; Migliaccio I; Guarducci C; Malorni L; Litchfield LM; Liu J; Donaldson J; Selenica P; Brown DN; Weigelt B; Reis-Filho JS; Park BH; Hurvitz SA; Slamon DJ; Rimawi MF; Jansen VM; Jeselsohn R; Osborne CK; Schiff R
Clin Cancer Res; 2021 Sep; 27(17):4870-4882. PubMed ID: 33536276
[TBL] [Abstract][Full Text] [Related]
4. Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation.
Quan C; Wu Z; Xiong J; Li M; Fu Y; Su J; Wang Y; Ning L; Zhang D; Xie N
Exp Hematol Oncol; 2023 Nov; 12(1):100. PubMed ID: 38037159
[TBL] [Abstract][Full Text] [Related]
5. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
[TBL] [Abstract][Full Text] [Related]
6. Arthralgia induced by endocrine therapy with or without cyclin-dependent kinase 4/6 inhibitors in breast cancer: A systematic review and meta-analysis.
Takatsuka D; Sawaki M; Hattori M; Yoshimura A; Kotani H; Kataoka A; Horisawa N; Ozaki Y; Endo Y; Nozawa K; Iwata H
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e175-e182. PubMed ID: 36085411
[TBL] [Abstract][Full Text] [Related]
7. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
8. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
[TBL] [Abstract][Full Text] [Related]
9. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
[TBL] [Abstract][Full Text] [Related]
10. The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer.
Gomes I; Abreu C; Costa L; Casimiro S
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835528
[TBL] [Abstract][Full Text] [Related]
11. Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
Pesch AM; Hirsh NH; Chandler BC; Michmerhuizen AR; Ritter CL; Androsiglio MP; Wilder-Romans K; Liu M; Gersch CL; Larios JM; Pierce LJ; Rae JM; Speers CW
Clin Cancer Res; 2020 Dec; 26(24):6568-6580. PubMed ID: 32967938
[TBL] [Abstract][Full Text] [Related]
12. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.
Zhao M; Hanson KA; Zhang Y; Zhou A; Cha-Silva AS
Target Oncol; 2023 May; 18(3):327-358. PubMed ID: 37074594
[TBL] [Abstract][Full Text] [Related]
13. First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study.
Basile D; Gerratana L; Corvaja C; Pelizzari G; Franceschin G; Bertoli E; Palmero L; Zara D; Alberti M; Buriolla S; Da Ros L; Bonotto M; Mansutti M; Spazzapan S; Cinausero M; Minisini AM; Fasola G; Puglisi F
Breast; 2021 Jun; 57():104-112. PubMed ID: 33812267
[TBL] [Abstract][Full Text] [Related]
14. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
15. Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer.
Kharenko OA; Patel RG; Calosing C; van der Horst EH
Cancer Gene Ther; 2022 Jun; 29(6):859-869. PubMed ID: 34385584
[TBL] [Abstract][Full Text] [Related]
16. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Wander SA; Cohen O; Gong X; Johnson GN; Buendia-Buendia JE; Lloyd MR; Kim D; Luo F; Mao P; Helvie K; Kowalski KJ; Nayar U; Waks AG; Parsons SH; Martinez R; Litchfield LM; Ye XS; Yu C; Jansen VM; Stille JR; Smith PS; Oakley GJ; Chu QS; Batist G; Hughes ME; Kremer JD; Garraway LA; Winer EP; Tolaney SM; Lin NU; Buchanan SG; Wagle N
Cancer Discov; 2020 Aug; 10(8):1174-1193. PubMed ID: 32404308
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
18. HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.
Zhang H; Wang J; Li J; Zhou X; Yin L; Wang Y; Gu Y; Niu X; Yang Y; Ji H; Zhang Q
Cancer Sci; 2021 Apr; 112(4):1603-1613. PubMed ID: 33453094
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.
Dang F; Nie L; Zhou J; Shimizu K; Chu C; Wu Z; Fassl A; Ke S; Wang Y; Zhang J; Zhang T; Tu Z; Inuzuka H; Sicinski P; Bass AJ; Wei W
Nat Commun; 2021 Sep; 12(1):5386. PubMed ID: 34508104
[TBL] [Abstract][Full Text] [Related]
20. Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan.
Sawaki M; Muramatsu Y; Togo K; Iwata H
Breast; 2023 Aug; 70():1-7. PubMed ID: 37267715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
